Sarepta's Promising Data Sparks Market Optimism

Written by Emily J. Thompson, Senior Investment Analyst

Source: stocktwits

Updated: 5 days ago

0mins

SRPT+2.55%

Should l Buy SRPT?

Source: stocktwits

Initial Clinical Results: Sarepta's early data from its investigational siRNA treatment SRP-1001 for neuromuscular diseases shows dose-dependent muscle exposure and favorable tolerability, although the limited DM1 data and ongoing safety debates suggest potential for improved clinical efficacy in the future.
Analyst Rating Changes: Oppenheimer analyst Kostas Biliouris maintains an ‘Outperform’ rating on Sarepta with a $37 price target, indicating optimism despite market concerns over early clinical results, and he looks forward to additional data expected in the second half of 2026.
Positive Market Reaction: Retail sentiment on Stocktwits for SRPT stock surged from ‘bullish’ to ‘extremely bullish’ in the past 24 hours, with message volume increasing from ‘low’ to ‘extremely high’, reflecting strong investor confidence in Sarepta's future potential.
Stock Price Volatility: Despite a 68% decline in Sarepta's stock over the past year, shares rose 35% on Wednesday, indicating market optimism regarding its new therapies, which may attract more investor interest moving forward.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SRPT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SRPT

Wall Street analysts forecast SRPT stock price to rise

18 Analyst Rating

4 Buy

10 Hold

4 Sell

Hold

Current: 19.970

Low

5.00

Averages

20.80

High

45.00

Current: 19.970

Low

5.00

Averages

20.80

High

45.00

Wedbush

Outperform

maintain

$29 -> $35

2026-03-26

New

Reason

Wedbush

Price Target

$29 -> $35

AI Analysis

2026-03-26

New

maintain

Outperform

Reason

Wedbush raised the firm's price target on Sarepta to $35 from $29 and keeps an Outperform rating on the shares after including SRP-1001 for facioscapulohumeral muscular dystrophy and SRP-1003 for myotonic dystrophy type 1 into valuation, based on positive preliminary data reported from the Phase 1/2 studies yesterday. Both SRP-1001 and SRP-1003 showed a strong safety profile with no dose limiting toxicities or treatment-related SAEs, as well as dose-dependent plasma exposure. Wedbush projects SRP-1001 and SRP-1003 to enter the U.S. market in 2031 and 2032, through accelerated approval pathway that other more advanced programs for the same indications have helped to established, with modest 20% and 10% probability of success, respectively. Despite the early stage of the programs, the firm sees the initial data as a critical step forward for Sarepta's siRNA portfolio to create significant value for the stock.

Deutsche Bank

Sell

maintain

$12 -> $14

2026-03-26

New

Reason

Deutsche Bank

Price Target

$12 -> $14

2026-03-26

New

maintain

Sell

Reason

Deutsche Bank raised the firm's price target on Sarepta to $14 from $12 and keeps a Sell rating on the shares. The company yesterday exported positive preliminary data for its ARWR-licensed siRNA assets, SRP-1001 and SRP-1003, which came in above investor expectations, the analyst tells investors in a research note. Deutsche, however, is surprised by the stock's 35% rally, given the small number of patients dosed, limited duration of treatment, lack of data from multiple ascending dose cohorts, lack of key biomarkers. The data could merit a stock move of 15%-20%, making the 35% rally overdone, contends the firm.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SRPT

Unlock Now

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

SAREPTA THERAPEUTICS, INC.: DEUTSCHE BANK INCREASES TARGET PRICE FROM $12 TO $14

4 days agomoomoo

Company Overview: Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases.
Recent Financial Update: Deutsche Bank has raised the target price for Sarepta Therapeutics from $12 to $14, indicating a positive outlook for the company's stock.

SAREPTA THERAPEUTICS INC: WEDBUSH INCREASES TARGET PRICE FROM $29 TO $35

4 days agomoomoo

Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Recent Price Increase: The company has raised its target price to $35 from a previous target of $29, indicating a positive outlook from analysts.
Market Impact: This price adjustment reflects growing confidence in Sarepta's pipeline and potential market performance.
Investor Sentiment: The increase in target price may influence investor sentiment and trading activity surrounding Sarepta Therapeutics' stock.

SAREPTA THERAPEUTICS INC: CITIGROUP INCREASES TARGET PRICE FROM $9 TO $13

4 days agomoomoo

Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Stock Price Increase: Citigroup has raised the price target for Sarepta Therapeutics' stock from $9 to $13, indicating a positive outlook on the company's future performance.

SAREPTA THERAPEUTICS INC: PIPER SANDLER INCREASES TARGET PRICE FROM $16 TO $23

5 days agomoomoo

Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Stock Price Increase: The company has raised its target price from $16 to $23, indicating a positive outlook and potential growth in its market valuation.